XML 48 R34.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Revenue (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Revenue from Contract with Customer [Abstract] |
Schedule of Revenue | Total revenues during the years ended December 31, 2023, 2022, and 2021 were as follows (in thousands):
| Year Ended December 31, |  |  |  |
| 2023 |  | 2022 |  | 2021 |  |  |  |  |  |  |
Product sales, net: |  |  |  |  |  |  |  |  |  |  |  |  |
IBSRELA | $ | 80,062 |  |  | $ | 15,600 |  |  | $ | — |  |  |  |  |  |  |  |  |
XPHOZAH | 2,464 |  |  | — |  |  | — |  |  |  |  |  |  |  |  |
Total product sales, net | 82,526 |  |  | 15,600 |  |  | — |  |  |  |  |  |  |  |  |
Licensing revenue | 35,809 |  |  | 35,031 |  |  | 5,013 |  |  |  |  |  |  |  |  |
Product supply revenue | 6,121 |  |  | 1,527 |  |  | 907 |  |  |  |  |  |  |  |  |
Collaborative development revenue | — |  |  | — |  |  | 4,177 |  |  |  |  |  |  |  |  |
Total revenues | $ | 124,456 |  |  | $ | 52,158 |  |  | $ | 10,097 |  |  |  |  |  |  |  |  |
Schedule of Revenue from Customers as a Percentage of Total Product Revenue, Net | Revenue from the following Customers who contributed greater than 10% of our gross product revenue during the years ended December 31, 2023 and 2022 as a percentage of total gross product revenue was as follows:
|  |  | Year Ended December 31,
|  |  |  |  | 2023 |  | 2022
BioRidge Pharma, LLC |  |  |  |  | 26.3 | % |  | — | %
Cardinal Health |  |  |  |  | 21.6 | % |  | 23.1 | %
AmerisourceBergen Drug Corporation |  |  |  |  | 20.9 | % |  | 26.8 | %
McKesson Corporation |  |  |  |  | 17.2 | % |  | 21.6 | %
Revenues from Customers and collaboration partnerships accounting for more than 10% of total revenues during the years ended December 31, 2023, 2022 and 2021 were as follows:
| Year Ended December 31,
| 2023 |  | 2022 |  | 2021
Kyowa Kirin | 29.0 | % |  | 70.0 | % |  | 100.0 | %
Bioridge Phama | 24.0 | % |  | 3.2 | % |  | — | %
Cardinal | 19.8 | % |  | 9.6 | % |  | — | %
AmerisourceBergen Drug Corporation | 19.1 | % |  | 11.1 | % |  | — | %
McKesson | 15.7 | % |  | 8.9 | % |  | — | %
Schedule of Chargebacks, Discounts and Reserve Balances | The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):
| Discounts and Chargebacks |  | Rebates, Wholesaler and GPO Fees |  | Copay and Returns |  | Total
Balance as of December 31, 2021 | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Provisions | 825 |  |  | 2,721 |  |  | 2,502 |  |  | 6,048 |
Credits/payments | (683) |  |  | (1,277) |  |  | (1,244) |  |  | (3,204) |
Balance as of December 31, 2022 | 142 |  |  | 1,444 |  |  | 1,258 |  |  | 2,844 |
Provisions | 5,341 |  |  | 15,365 |  |  | 10,629 |  |  | 31,335 |
Credits/payments | (5,005) |  |  | (12,575) |  |  | (7,971) |  |  | (25,551) |
Balance as of December 31, 2023 | $ | 478 |  |  | $ | 4,234 |  |  | $ | 3,916 |  |  | $ | 8,628 |

X
- Definition Schedule Of Gross To Net Sales Accruals + References No definition available. + Details
Name: | ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock
Namespace Prefix: | ardx_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration